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AbstrACt
Introduction Use of patch angioplasty in carotid 
endarterectomy (CEA) is suggested to reduce the risk 
of restenosis and recurrent ipsilateral stroke. The 
objective is to conduct a systematic review with meta-
analysis and trial sequential analysis as well as Grading 
of Recommendations Assessment, Development and 
Evaluation (GRADE) assessments comparing the benefits 
and harms of CEA with primary closure of the arterial 
wall versus CEA with patch angioplasty in patients with a 
symptomatic and significant carotid stenosis.
Methods and analysis The review shall be conducted 
according to this published protocol following the 
recommendations of the ‘Cochrane’ and reported 
according to the Preferred Reporting Items for Systematic 
Reviews and Meta-Analyses statement. Randomised 
clinical trials comparing CEA with primary closure of 
the arterial wall versus CEA with patch angioplasty 
(regardless of used patch materials) in human adults 
with a symptomatic and significant carotid stenosis will 
be included. Primary outcomes are all-cause mortality 
at maximal follow-up, health-related quality of life 
and serious adverse events. Secondary outcomes are 
symptomatic or asymptomatic arterial occlusion or 
restenosis, and non-serious adverse events. We will 
primarily base our conclusions on meta-analyses of trials 
with overall low risk of bias. However, if pooled point 
estimates of all trials are similar to pooled point estimates 
of trials with overall low risk of bias and there is lack of a 
statistical significant interaction between estimates from 
trials with overall high risk of bias and trials with overall 
low risk of bias we will consider the precision achieved in 
all trials as the result of our meta-analyses.
Ethics and dissemination The proposed systematic 
review will collect and analyse secondary data from 
published studies therefor ethical approval is not required. 
The results of the systematic review will be disseminated 
by publication in a peer-review journal and submitted for 
presentation at relevant conferences.
PrOsPErO registration number CRD42014013416.
IntrOduCtIOn
Carotid artery stenosis occurs due to athero-
sclerosis and was described to be a patholog-
ical substrate for ischaemic diseases of the 
ipsilateral brain and eye by C Miller Fisher 
in 1951.1 Preventive management of asymp-
tomatic carotid artery stenosis includes anti-
platelets, statins, antihypertensives, diabetic 
control as well as lifestyle modifications.2–4 
There is still discussion about the severity of 
the stenosis for surgical treatment and the 
way the severity of the stenosis should be 
assessed. Carotid endarterectomy (CEA) is 
the preferred treatment for patients with a 
symptomatic and significant (>70%) stenosis 
of the carotid artery,5 primarily based on 
the European Carotid Surgery Trial and the 
strengths and limitations of this study
 ► The review shall be conducted according to this 
published protocol following the recommendations 
of the ‘Cochrane’ and reported according to the 
Preferred Reporting Items for Systematic Reviews 
and Meta-Analyses statement.
 ► Trial sequential analysis compared with GRADE as-
sessments of randomised clinical trials are included.
 ► This review benefits from a comprehensive search 
strategy, designed to retrieve a broad spectrum of 
relevant articles for the research question.
 ► To avoid design error, one technique will be com-
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North American Symptomatic Carotid Endarterectomy 
Trial.6–8 
Restenosis after CEA occurs in 6%–36% of patients 
during long-term follow-up of at least 12 months.9–13 Two 
operation techniques are well known in literature: the 
eversion technique and the traditional endarterectomy 
using a longitudinal arteriotomy. Closure in both tech-
niques can be achieved by either direct suturing of the 
arterial wall or patch angioplasty in CEA.14 Use of patch 
angioplasty in CEA is suggested to reduce both the risks 
of restenosis and recurrent ipsilateral stroke.15
Guidelines of both the European Society of Vascular 
Surgery and the Dutch Society for Vascular Surgery 
consider CEA with patch angioplasty as the reference 
technique.8 16 17 A meta-analysis of 10 randomised clinical 
trials (RCTs) including 2157 operations in 1967 patients 
compared CEA with primary closure versus CEA with 
patch angioplasty and concluded that CEA with patch 
angioplasty may reduce the risks of restenosis, perioper-
ative arterial occlusion and ipsilateral stroke.15 However, 
the observed differences in intervention effects may be 
explained by several confounding factors and/or differ-
ential use of cointerventions, such as the use of periop-
erative transcranial Doppler monitoring, perioperative 
carotid pressure measurement, electroencephalographic 
monitoring, selected use of shunting, regional anaes-
thesia and variations in materials used for patching.18–25
To determine which technique, CEA with a primary 
closure of the arterial wall or CEA with use of patch angio-
plasty is more effective for a symptomatic and significant 
(>70%) carotid stenosis, it is important that all available 
evidence is evaluated according to the risks of errors in 
a systematic review in line with the Cochrane Handbook 
for Systematic Reviews of Interventions.26 27 Therefore, a 
proper and updated systematic review with meta-analyses 
and Trial Sequential Analysis (TSA) is needed, including 
GRADE assessments of the evidence.
Objective
The objective is to conduct a systematic review with 
meta-analysis and TSA of RCTs, evaluating the benefits 
and harms of the primary closure versus patch angioplasty 
in CEA according to a prepublished protocol following 
the Cochrane Handbook for Systematic Reviews of 
Interventions.26
MEthOds
This review will be conducted according to this protocol 
which is also registered at PROSPERO since 2014 and was 
updated at October 2018 (http://www. crd. york. ac. uk/ 
PROSPERO/ display_ record. php? ID= CRD42014013416) 
following the recommendations of the ‘Cochrane Hand-
book for Systematic Reviews of interventions’26 and will 
be reported according to the Preferred Reporting Items 
for Systematic Reviews and Meta-Analyses statement (at: 
www. prisma- statement. org).28
studies
Only RCTs comparing CEA with primary closure of the 
arterial wall versus CEA with patch angioplasty (regard-
less of used patch materials) will be included. Trials 
will be considered irrespective of language, blinding, 
outcomes or publication status. We will also consider 
quasi-randomised studies, controlled clinical studies and 
other observational studies for data on harm if retrieved 
with our searches for RCTs. This is because adverse events 
are rarely reported in RCTs.29 Moreover, such observa-
tional studies may provide information on rare or late 
occurring adverse events.29 We are aware that the deci-
sion not to search for all observational studies may bias 
our review towards assessment of benefits and may over-
look certain harms, such as late or rare harms.
Patients
According to the current guidelines,6–8 patients with a 
symptomatic and significant stenosis (>70%, measured by 
computed tomographic angiography or magnetic reso-
nance angiography) of the carotid artery will be consid-
ered. Repeated Doppler ultrasound or digital subtraction 
angiography is possible as an imaging modality to measure 
the degree of the carotid stenosis, but the threshold of 
stenosis should be at least 70%. Only trials which evaluate 
CEA in adult patients (≥18 years) will be included.17 We 
are aware of the guideline statement that CEA may be 
considered in symptomatic internal carotid lesions of 
<70%. Studies in children and animals will be excluded.
Experimental intervention
The experimental intervention is traditional CEA (longi-
tudinal arteriotomy) with primary closure of the arte-
rial wall.14 RCTs which compare the eversion technique 
with patch angioplasty will be excluded.30 Because of 
comparing two techniques, the eversion technique will 
be investigated in a separate systematic review, we want to 
compare one experimental intervention to one control 
intervention to prevent design error.
Control intervention
The control intervention is CEA with patch angioplasty 
regardless of the type of patch material used.14
Cointerventions
Intraoperative monitoring may vary in the trials such as 
the use of perioperative transcranial Doppler monitoring, 
perioperative carotid pressure measurement and elec-
troencephalographic monitoring. Other intraoperative 
cointerventions may also vary in the trials, for example, 
the selected use of shunting and the use of variations in 
materials used for patching.
Outcomes
The outcome measures will be graded from the patients’ 
perspective (GRADE Working Group 2008, online supple-
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Primary outcomes
 ► All-cause mortality.
 ► Proportion of participants with one or more serious 
adverse events; that is, any untoward medical occur-
rence that results in death, is life-threatening, requires 
hospitalisation or prolongation of existing hospitali-
sation, results in persistent or significant disability or 
incapacity.32
 ► Health-related quality of life: any scale used by trialists 
to assess the participants' reporting of their quality of 
life.
Secondary outcomes
 ► Symptomatic or asymptomatic (50%–99%) arterial 
occlusion or restenosis.
 ► Proportion of participants with one or more non-se-
rious adverse events: any untoward medical occur-
rence in a participant who does not meet the above 
criteria for a serious adverse event is defined as a 
non-serious adverse event.32
Exploratory outcomes
 ► Separately reported serious adverse events.
 ► Separately reported non-serious adverse events.
The numbers of patients with one or more complica-
tions will be evaluated rather than the numbers of events, 
depending on the availability of data.
search strategy
The Cochrane Central Register of Controlled Trials in 
The Cochrane Library, PubMed/MEDLINE and EMBASE 
will be searched. References of the identified trials will be 
searched to identify any further relevant RCTs. The search 
strategies are provided in online supplementary appendix 
2. Searches will include MeSH descriptors such as ‘Clin-
ical Trials’, ‘carotid endarterectomy’, ‘thromboendarter-
ectomy’ and ‘carotid artery disease’. We will also search 
online trial registries such as  ClinicalTrials. gov (https:// 
clinicaltrials. gov/), European Medicines Agency ( www. 
ema. europa. eu/ ema/), WHO International Clinical 
Trial Registry Platform ( www. who. int/ ictrp) and the Food 
and Drug Administration ( www. fda. gov) for ongoing or 
unpublished trials. In addition, we plan to search Google 
Scholar (https:// scholar. google. nl/) using the term 
carotid endarterectomy in title.
data collection
Two authors will perform screening and select the trials for 
inclusion, independently. Excluded trials and studies will 
be listed with their reasons for exclusion. While disagree-
ments may occur, a third author will be approached to 
reconcile. The authors will extract the following data: trial 
characteristics (year and language of publication, country 
in which the trial was conducted, year of conduction of 
the trial, single or multicenter trial, number of patients), 
patient characteristics (inclusion and exclusion criteria, 
mean age, mean body mass index and gender, smoking, 
diabetes mellitus, use of statin and platelet inhibitors), 
intervention characteristics (primary closure, closure by 
patch, use of shunting), cointerventions (local or general 
anaesthesia, perioperative transcranial Doppler moni-
toring, perioperative carotid pressure measurement, 
electroencephalographic monitoring) and the outcome 
measures evaluated.
If there are any unclear or missing data, the corre-
sponding authors of the individual trials will be contacted 
at least twice.
risk of bias assessment
Two authors will assess the risks of bias, without masking 
for trial names, according to the Cochrane Handbook 
for Systematic Reviews of Interventions,26 including the 
domains of generation of the allocation sequence, allo-
cation concealment, blinding of participants, personnel, 
and outcome assessors, incomplete outcome data, selec-
tive outcome reporting and other bias risks such as vested 
interests. Risk of bias components will be scored as low, 
unclear or high risk of bias. Trials will be classified as trials 
at low overall risk of bias if all risk of bias domains are 
scored as having low risk of bias. If one or more of the bias 
domains are scored as unclear or at high risk of bias, the 
trial will be considered at high overall risk of bias.27 33 34
sequence generation
 ► Low risk of bias: the method used (eg, central alloca-
tion) is unlikely to induce bias on the final observed 
effect, such as:
 – Referring to a random number table.
 – Using a computer random number generator.
 – Coin tossing.
 – Shuffling cards or envelopes.
 – Throwing dice.
 – Drawing of lots.
 ► Unclear risk of bias: insufficient information to 
assess whether the method used is likely to introduce 
confounders.
 ► High risk of bias: the method is improper and likely of 
introduce confounding, for example, based on date 
of admission, or record number, or by odd or even 
date of birth.
Allocation concealment
 ► Low risk of bias: participants and investigators 
enrolling participants could not foresee assign-
ment because one of the following, or an equivalent 
method, was used to conceal allocation:
 – Central allocation (including telephone).
 – Web-based and pharmacy-controlled 
randomisation.
 – Sequentially numbered drug containers of identi-
cal appearance.
 – Sequentially numbered, opaque, sealed envelopes.
 ► Unclear risk of bias: insufficient information to 
permit judgement of ‘low risk’ or ‘high risk’. This is 
usually the case if the method of concealment is not 
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 ► High risk of bias: participants or investigators enrolling 
participants could possibly foresee assignments and 
thus introduce selection bias, such as allocation based 
on:
 – An open random allocation schedule.
 – Assignment envelopes were used without appropri-
ate safeguards.
 – Alternation or rotation.
 – Date of birth.
 – Case record number.
 – Any other explicitly unconcealed procedure.
blinding of participants and personnel
In surgical procedures, it is impossible to blind the 
surgeon who performs the procedure of CEA, while it is 
possible to blind the caregivers responsible for postopera-
tive care as well as the patients.35 For this domain, we will 
consider the caregivers and patients and not the surgeon 
who performs the procedure, although a certain risk of 
bias will inevitably be present when evaluating surgical 
procedures. The statistician who performs the analyses 
can be blinded.
 ► Low risk of bias: no blinding or incomplete blinding, 
but the review authors judge that the outcome is not 
likely to be influenced by lack of blinding or blinding 
of participants and key study personnel ensured, 
and it is unlikely that the blinding could have been 
broken.
 ► Unclear risk of bias: insufficient information to permit 
judgement of low risk or high risk, or the study did 
not address this outcome.
 ► High risk of bias: no blinding or incomplete blinding, 
and the outcome is likely to be influenced by lack of 
blinding or blinding of key study participants and 
personnel attempted, but likely that the blinding 
could have been broken, and the outcome is likely to 
be influenced by lack of blinding.
blinding of outcome assessment
 ► Low risk of bias: no blinding of outcome assess-
ment, but the review authors judge that the outcome 
measurement is not likely to be influenced by lack 
of blinding or blinding of outcome assessment is 
ensured, and it is unlikely that the blinding could 
have been broken.
 ► Unclear risk of bias: insufficient information to permit 
judgement of low risk, or high risk or the study did 
not address this outcome.
 ► High risk of bias: no blinding of outcome assessment, 
and the outcome measurement is likely to be influ-
enced by lack of blinding, or blinding of outcome 
assessment, but likely that the blinding could have 
been broken, and the outcome measurement is likely 
to be influenced by lack of blinding.
Incomplete outcome data
 ► Low risk of bias:
 – No missing outcome data.
 – Reasons for missing outcome data unlikely to be re-
lated to true outcome (for survival data, censoring 
unlikely to be introducing bias).
 – Missing outcome data balanced in numbers across 
intervention groups, with similar reasons for miss-
ing data across groups.
 – For dichotomous outcome data, the proportion of 
missing outcomes compared with observed event 
risk is not enough to have a clinically relevant im-
pact on the intervention effect estimate.
 – For continuous outcome data, plausible effect size 
(difference in means or standardised difference in 
means) among missing outcomes is not enough to 
have a clinically relevant impact on observed effect 
size.
 – Missing data have been imputed using appropriate 
methods.
 ► Unclear risk of bias: insufficient reporting of attri-
tion/exclusions to permit judgement of low risk or 
high risk (eg, number randomised not stated, no 
reasons for missing data provided) or the study did 
not address this outcome.
 ► High risk of bias:
 – Reason for missing outcome data likely to be relat-
ed to true outcome, with either imbalance in num-
bers or reasons for missing data across intervention 
groups.
 – For dichotomous outcome data, the proportion of 
missing outcomes compared with observed event 
risk enough to induce clinically relevant bias in in-
tervention effect estimate.
 – For continuous outcome data, plausible effect size 
(difference in means or standardised difference 
in means) among missing outcomes enough to in-
duce clinically relevant bias in observed effect size.
 – ‘As-treated’ analysis done with substantial depar-
ture of the intervention received from that as-
signed at randomisation.
 – Potentially inappropriate application of simple 
imputation.
selective outcome reporting
 ► Low risk of bias: the study protocol is available and 
all the studies prespecified (primary and secondary) 
outcomes that are of interest in the review have been 
reported in the prespecified way, or the study protocol 
is not available but it is clear that the published reports 
include all expected outcomes, including those that 
were prespecified.
 ► Unclear risk of bias: insufficient information to permit 
judgement of low risk or high risk. It is likely that the 
majority of studies will fall into this category.
 ► High risk of bias:
 – Not all of the studies prespecified primary out-
comes have been reported.
 – One or more primary outcomes is reported using 
measurements, analysis methods or subsets of the 
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 – One or more reported primary outcomes were not 
prespecified (unless clear justification for their re-
porting is provided, such as an unexpected adverse 
effect).
 – One or more outcomes of interest in the review are 
reported incompletely so that they cannot be en-
tered in a meta-analysis.
 – The study report fails to include results for a key 
outcome that would be expected to have been re-
ported for such a study.
Other bias
 ► Low risk of bias: the study appears to be free of other 
sources of bias.
 ► Unclear risk of bias: there may be a risk of bias, but 
there is either insufficient information to assess 
whether an important risk of bias exists or insufficient 
rationale or evidence that an identified problem will 
introduce bias.
 ► High risk of bias: there is at least one important risk 
of bias.
statistical methods
Meta-analyses will be performed according to the 
Cochrane Handbook for Systematic Reviews of Interven-
tions.26 The software package Review Manager (RevMan) 
V.5.3 will be used.36 Significance levels will be adjusted 
due to multiplicity of several outcomes. The results of 
each outcome will be determinative for the use of the 
intervention and requires an adjusted statistical signif-
icance level (threshold). An alfa of (0.05/ ((1+3)/2)=) 
0.025 will be used for the primary outcomes to keep the 
family wise error rate <0.05. For the secondary outcomes, 
this will be 0.033.37 38 For exploratory outcomes, we will 
consider a p value <0.05 as significant, because we view 
these outcomes as only hypothesis-generating outcomes. 
For dichotomous variables, the risk ratio with TSA-ad-
justed CIs will be calculated. For continuous variables, the 
mean difference (MD) or the standardised mean differ-
ence with 95% CI will be calculated.
For the outcome of serious adverse events (SAE), we 
plan to estimate the proportion of patients with one or 
more SAE in each group and to analyse this outcome 
in a binary meta-analysis. However, as we anticipate the 
reporting of SAEs in trials to vary considerably we plan to 
do two analyses:
 ► Assuming that only one SAE is reported per patient 
we will add all reported SAE in each trial and calcu-
late the proportion of summed SAE divided with 
number of randomised patients in the experimental 
and control intervention group (worst case scenario).
 ► To avoid multiple counts of SAE in the same patients 
(SAE counting is not a statistical independent 
outcome) we will also analyse the most frequent SAE 
as if it represents the total number of SAEs in the 
experimental and control intervention group (best 
case scenario). Being aware that none of these inter-
vention effect estimates are exactly correct we will 
discuss them as possible worst and best case scenarios 
for the effect of the experimental versus the control 
intervention on the proportion of patients with one 
or more SAEs.
The impact of attrition bias will be explored using best/
worst and worst/best case scenarios: a best/worst case 
scenario is one where all patients lost to follow-up in the 
intervention group are supposed to have survived while 
all patients lost to follow-up in the control intervention 
group have died. A worst/best case scenario is the reverse.
Heterogeneity will be explored by χ2 test with signifi-
cance set at p value of 0.10, and the quantity of hetero-
geneity will be measured by I2. We will conduct both 
random-effects model and fixed-effect model meta-anal-
yses. In case of discrepancies, the results of both models 
will be presented and we will primarily stress the result of 
the model with the result closet to null effect due to prin-
ciple of cautiousness.38 The analyses will be performed on 
an intention-to-treat basis whenever possible.
A funnel plot will be used to explore small trial bias and 
to use asymmetry in funnel plot of trial size against treat-
ment effect to assess this bias. Begg’s and Egger’s tests will 
be used to test for asymmetry in funnel plots.39
trial sequential analyses
Meta-analyses may result in type I errors and type II errors 
due to an increased risk of random error when sparse 
data are analysed and due to repeated significance testing 
when a cumulative meta-analysis is updated with new 
trials.40 41 To assess the risk of type I and type II errors, 
TSA will be used. The vast majority of meta analyses 
(~80%) in Cochrane systematic reviews have less than the 
required information size to conclude on a 30% relative 
risk reduction (RRR) and <2% have sufficient power to 
conclude on a 10% RRR.42–44
TSA combines information size estimation for 
meta-analysis (cumulated sample size of included trials) 
with an adjusted threshold for statistical significance 
of meta-analysis.40 41 45 The latter, called trial sequential 
monitoring boundaries (TSMBs), reduce type I errors. In 
TSA, the addition of each trial in a cumulative meta-anal-
ysis is regarded as an interim analysis and helps to clarify 
whether additional trials are needed or not. The idea 
in TSA is that when the cumulative z-curve crosses the 
TSMB, a sufficient level of evidence has been reached 
and no further trials may be needed. If the z-curve does 
not cross the boundary of benefit and the required infor-
mation size has not been reached, there may be insuf-
ficient evidence to reach a conclusion.40 41 46 47 TSA can 
also be used for the evaluation of type II errors, that is, 
to evaluate whether further randomised trial is futile to 
show or discard the anticipated intervention effect (RRR 
or MD). This happens when the cumulative z-curve does 
cross the TSMBs for futility. TSA will be applied since it 
controls the risks of type I and type II errors in a cumu-
lative meta-analysis and may provide important informa-
tion on how many more patients need to be included in 
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diversity-adjusted required information size (DARIS).48 
We will do the primary analysis calculating the DARIS 
based on an a priori anticipated intervention effect of a 
10% RRR which is close to a minimal important difference 
and sensitivity analyses for a 15% RRR as well as a the RRR 
suggested by the meta-analysis of the included trials.49 If 
the estimated diversity of the meta-analysis is 0%, a sensi-
tivity analysis with TSA using a diversity of 25% will be 
conducted. TSA will be performed on all outcomes. The 
required information size for primary outcomes will be 
calculated based on an a priori RRR of 10% and appropri-
ately adjusted for diversity according to an overall type I 
error of 5% and a power of 90% considering early and 
repetitive testing.48 For secondary outcomes, the DARIS 
will be calculated using a power of 80%.48
As a sensitivity analysis, the DARIS will be calculated 
using the estimated intervention effect from the trials 
at low risk of bias in a conventional meta-analysis. If the 
required information size is surpassed for the TSA using 
the estimated intervention effect in the conventional 
meta-analysis or a TSMB is crossed a TSA with an antic-
ipated intervention effect equal to the confidence limit 
closest to the null effect in the effect estimate from the 
conventional meta-analysis will be performed. The TSAs 
will be conducted using the control event proportion 
calculated from the unweighted control event proportion 
from the control groups of the actual meta-analyses.
subgroup analyses
The following subgroup analyses will be performed:
 ► trials at overall low risk of bias (all except blinding 
of surgeons scored as low risk of bias) compared with 
trials at high overall risk of bias (one or more of the 
bias domains [excluding blinding of surgeons] scored 
as unclear or high risk).
 ► different patch materials may be used including 
venous, polytetrafluorethylene, Dacron and 
biopatches (bovine/porcine).25 Subgroup analyses 
will be conducted according availability of data on 
different materials.
GrAdE
Summary of findings tables will be produced summarising 
the results of the trials with overall low risk of bias and for 
all trials, separately. Reasons for downgrading the quality 
of the available evidence are risk of bias evaluation of the 
included bias domains, publication bias, heterogeneity, 
imprecision and indirectness (eg, length of stay is a surro-
gate outcome measure).50–52 We will compare the impre-
cision assessed according to GRADE with that of TSA.53
Patient and public involvement
Patients and/or public were not involved in this study.
EthICs And dIssEMInAtIOn
The results of the systematic review will be disseminated 
by publication in a peer-review journal and submitted for 
presentation at relevant conferences.
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